
WTM Visual Intelligence · Conceptual imagery
Examine health through scientific evidence, care, public systems and the human experience of wellbeing.

GM’s decision to stop funding Cruise’s robotaxi model while retaining autonomy capability reveals a difficult leadership discipline: knowing which ambition to preserve and which mechanism to end. WTM examines capital, safety reporting, integration, human consequences and the board practices that make strategic stopping accountable.

People with Laron syndrome have helped researchers investigate how growth signalling affects cancer risk. Studies of an Ecuadorian cohort report unusually low cancer incidence, but not immunity or a proven cure. This editorial examines the evidence, the limits of the research and what a rare condition can reveal about a wider biological system.

Trust is frequently treated as a sentiment: desirable, fragile and difficult to measure. Marc Blakeman Senior Vice President at Comcast, sees something more operational. Across decades in government affairs, public policy and institutional leadership — including his current role as Senior Vice President of Government and Community Affairs at Comcast — he has learnt that trust determines whether people will follow a leader, believe an institution, tolerate a mistake or remain in relationship when circumstances become difficult. In this WTM Conversation, Marc Blakeman and Kelly Dowd, MBA, MA, Editor-In-Chief, WTM Media | Why These Matter, and Host, The WTM Conversations, examine leadership beyond charisma, institutional credibility beyond communications strategy, reputation before crisis, the changing architecture of public communication and what artificial intelligence may make more — rather than less — valuable about human judgement. The central intelligence is deceptively simple: communication cannot manufacture institutional character. It can only make character visible. In an age capable of producing more information, faster, the institutions that endure may be those that understand that trust is not messaging. It is accumulated evidence.

For most of aviation history, human flight has required an aircraft: a machine large enough to generate lift, carry fuel, accommodate passengers, and surround its occupants with an engineered structure. Emerging personal-flight technologies are beginning to loosen that relationship. Jet suits, powered wings, compact electric vertical-lift systems, autonomous drones, and increasingly sophisticated flight-control technologies suggest that aviation may eventually encompass machines worn, mounted, or summoned rather than conventionally boarded. The viral spectacle is irresistible. A person rises from the ground, accelerates over water, and appears to have acquired a superpower. Yet spectacle obscures the engineering. Human-scale powered flight confronts brutal constraints involving energy density, heat, noise, stability, endurance, payload, weather, redundancy, training, regulation, and the consequences of mechanical failure. A technology can fly successfully and still be unsuitable for mass transportation. That distinction is central to understanding personal aviation. The most plausible near-term applications are unlikely to involve commuters casually flying between homes and offices. Specialist environments — emergency response, defence, offshore infrastructure, inaccessible terrain, inspection, rescue, and certain industrial operations — provide a more credible pathway because the economic value of reaching somewhere quickly can outweigh the technology’s considerable limitations. The deeper development, however, extends beyond jet suits. Aviation is becoming computational. Sensors can stabilise machines faster than human reflexes. Software can continuously adjust thrust. Lightweight materials reduce mass. Autonomous navigation increasingly separates piloting from constant manual control. Electric propulsion enables aircraft configurations that would have been impractical under traditional mechanical architectures. The result is not necessarily the death of the aeroplane. Commercial aircraft remain extraordinarily efficient at moving large numbers of people over long distances. Instead, aviation may be fragmenting into a richer ecosystem: aircraft for distance, drones for autonomous logistics, eVTOL systems for specialised regional movement, and wearable or highly compact systems for particular human-scale missions. The important question is therefore no longer simply, “Can a person fly without an aeroplane?” We already know that certain machines can make that possible. The better question is: when does removing the aircraft make flight more useful?

Canada’s Medical Assistance in Dying programme has moved an ancient human question into modern medicine: when suffering becomes intolerable, who should have authority over how life ends? In 2024, 16,499 people received MAID—5.1 per cent of deaths in Canada. Yet the headline conceals crucial distinctions: 95.6 per cent were people whose natural deaths were reasonably foreseeable; 4.4 per cent were not. Most recipients had received palliative care, while disability advocates, clinicians, ethicists and policymakers continue to dispute whether safeguards can adequately separate autonomous choice from suffering intensified by inadequate social support. The future makes the question harder. Medicine is simultaneously extending life, managing once-fatal disease, expanding organ transplantation and developing technologies that could prolong healthy longevity. A civilisation capable of keeping people alive for longer must therefore become equally sophisticated about what makes continued life worth living. The central question is larger than MAID: can a society protect the right to choose death without allowing failures of care to narrow the possibility of choosing life?

For four decades, the central challenge of HIV medicine has been control. Antiretroviral therapy can suppress the virus so effectively that people living with HIV can lead long, healthy lives and, when viral load remains undetectable, do not transmit HIV sexually. Yet treatment does not remove the latent viral reservoir embedded within the body, meaning therapy usually must continue. A developing body of HIV research is asking a different question: rather than continually suppressing an active virus, could medicine make its hidden genetic machinery remain silent? A 2025 Science Advances study found that an HIV-derived antisense transcript known as AST could reinforce viral latency in cells from people receiving treatment. Subsequent research confirmed that HIV antisense transcripts occur naturally in people living with the virus. These findings do not constitute an HIV cure. They reveal something potentially more consequential: another biological mechanism that scientists may eventually learn to manipulate. The larger intelligence is about where medicine may be heading—from repeatedly controlling disease towards redesigning the conditions that allow disease to persist.